HCA vs MDT

HCA Healthcare trades near its 52-week high with strong price momentum, up 37.9% over the past year and 225.1% over five years, reflecting sustained operational outperformance. The company delivered robust YoY earnings growth of 42.6%, supported by consistent quarterly beats—21 of the last 25 quarters—and accelerating revenue growth at 9.6%. Despite a premium valuation relative to some peers, HCA’s profitability metrics, including a 15.47% operating margin and 12.20% ROA, are industry-leading and justify the multiple. Analysts are aligned with a 'buy' recommendation and a $477.57 target price, implying modest upside, while insider selling remains limited in volume and likely routine.

Medtronic exhibits a stable but uninspiring financial profile, evidenced by a Piotroski F-Score of 4/9. While the company maintains a strong balance sheet with a Current Ratio of 2.54 and low Debt/Equity (0.57), it is currently facing a severe technical downtrend and negative earnings growth (-11.8% YoY). There is a significant valuation gap, as the current price of $79.37 trades well above the Graham Number ($55.45) and the growth-based Intrinsic Value ($25.06). The divergence between bullish analyst targets ($108) and bearish insider activity/price action suggests a period of high uncertainty.